Literature DB >> 29657017

Assessment of the antigenic and neuroprotective activity of the subunit anti-Toxoplasma vaccine in T. gondii experimentally infected mice.

Justyna Gatkowska1, Marek Wieczorek2, Bożena Dziadek3, Katarzyna Dzitko4, Jarosław Dziadek5, Henryka Długońska6.   

Abstract

The aim of this study was to evaluate the immunogenic and immunoprotective activities and to determine the neuroprotective capacity of the tetravalent vaccine containing selected recombinant T. gondii antigens (ROP2 + ROP4 + SAG1 + MAG1) administered with safe adjuvants (MPL and alum) using male and female inbred mice. The tested antigenic combination provided partial protection against brain cyst formation, especially in males (reduction in cyst burden by 72%). The decrease in cyst burden was observed for the whole brain as well as for specified brain regions associated with natural defensive behaviors, emotion processing and integration of motor and sensory stimuli. The vaccine triggered a strong, specific immune response, regardless of sex, which was characterized by the antigen-specific in vitro synthesis of cytokines (IL-2, IFN-γ and IL-10) and in vivo production of systemic IgG1 and IgG2a immunoglobulins. Immunization prior to the parasite challenge seemed to influence T. gondii - associated behavioral and neurochemical changes, although the impact of vaccination strongly depended on sex and time post-infection. Interestingly, in the vaccinated and T. gondii infected mice there was a significant delay in the parasite-induced loss of aversion toward cat smell (cats are the definitive hosts of the parasite). The regained attraction toward feline scent in vaccinated males, observed during chronic parasite invasion, correlated with the increase in the dopamine metabolism.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Behavioral changes; Brain neurochemistry; Central nervous system; Immunoprotection; Recombinant antigens; Toxoplasmosis

Mesh:

Substances:

Year:  2018        PMID: 29657017     DOI: 10.1016/j.vetpar.2018.02.043

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  3 in total

1.  Mucosal Administration of Recombinant Baculovirus Displaying Toxoplasma gondii ROP4 Confers Protection Against T. gondii Challenge Infection in Mice.

Authors:  Keon-Woong Yoon; Ki-Back Chu; Hae-Ji Kang; Min-Ju Kim; Gi-Deok Eom; Su-Hwa Lee; Eun-Kyung Moon; Fu-Shi Quan
Journal:  Front Cell Infect Microbiol       Date:  2021-09-29       Impact factor: 5.293

Review 2.  Toxoplasma gondii vaccine candidates: a concise review.

Authors:  Amirreza Javadi Mamaghani; Anwar Fathollahi; Zahra Arab-Mazar; Kobra Kohansal; Matin Fathollahi; Adel Spotin; Homayoon Bashiri; Arezoo Bozorgomid
Journal:  Ir J Med Sci       Date:  2022-04-08       Impact factor: 1.568

3.  Orally Administrated Recombinant Vaccinia Virus Displaying ROP4 Induces Protection against Toxoplasma gondii Challenge Infection.

Authors:  Keon-Woong Yoon; Ki-Back Chu; Hae-Ji Kang; Min-Ju Kim; Gi-Deok Eom; Fu-Shi Quan
Journal:  Vaccines (Basel)       Date:  2022-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.